PATENT CLAIM ANALYSIS

Application Number: 15979041
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "402000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 81):
The method of  claim 76  wherein the combinatorial regime is a combinatorial regime selected from the group consisting of:\n (a) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing immunoactivity; \n (b) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing macrophage activation; \n (c) use in a combinatorial regime as a chemotherapeutic agent with at least one cytokine; \n (d) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inhibiting telomerase; \n (e) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inhibiting survivin; \n (f) use in a combinatorial regime as a chemotherapeutic agent with at least one agent inducing demethylation; \n (g) use in a combinatorial regime as a chemotherapeutic agent with at least one adjuvant; \n (h) use in a combinatorial regime as a chemotherapeutic agent with at least one antibody; \n (i) use in a combinatorial regime as a chemotherapeutic agent with at least one innate or adaptive immune stimulator; \n (j) use in a combinatorial regime as a chemotherapeutic agent with at least one checkpoint inhibitor; \n (k) use in a combinatorial regime as a chemotherapeutic agent with at least one mTOR antagonist; \n (l) use in a combinatorial regime as a chemotherapeutic agent with at least one Akt inhibitor; \n (m) use in a combinatorial regime as a chemotherapeutic agent with at least one notch inhibitor; \n (n) use in a combinatorial regime as a chemotherapeutic agent with at least one HSP inhibitor; \n (o) use in a combinatorial regime as a chemotherapeutic agent with at least one phosphatidylinositide 3-kinase inhibitor; \n (p) use in a combinatorial regime as a chemotherapeutic agent with at least one kinase inhibitor; \n (q) use in a combinatorial regime as a chemotherapeutic agent with cytarabine; \n (r) use in a combinatorial regime as a chemotherapeutic agent with taxane; \n (s) use in a combinatorial regime as a chemotherapeutic agent with taxol; \n (t) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inducing telomerase inhibition; \n (u) use in a combinatorial regime as an agent inducing macrophage activation with at least one cytokine; \n (v) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inhibiting survivin; \n (w) use in a combinatorial regime as an agent inducing macrophage activation with at least one agent inducing demethylation; \n (x) use in a combinatorial regime as an agent inducing macrophage activation with at least one adjuvant; \n (y) use in a combinatorial regime as an agent inducing macrophage activation with at least one antibody; \n (z) use in a combinatorial regime as an agent inducing macrophage activation with at least one innate or adaptive immune stimulator; \n (aa) use in a combinatorial regime as an agent inducing macrophage activation with at least one checkpoint inhibitor; \n (ab) use in a combinatorial regime as an agent inducing macrophage activation with at least one mTOR antagonist; \n (ac) use in a combinatorial regime as an agent inducing macrophage activation with at least one Akt inhibitor; \n (ad) use in a combinatorial regime as an agent inducing macrophage activation with at least one notch inhibitor; \n (ae) use in a combinatorial regime as an agent inducing macrophage activation with at least one HSP inhibitor; \n (af) use in a combinatorial regime as an agent inducing macrophage activation with at least one phosphatidylinositide 3-kinase inhibitor; \n (ag) use in a combinatorial regime as an agent inducing macrophage activation with at least one kinase inhibitor; \n (ah) use in a combinatorial regime as an agent inducing macrophage activation with cytarabine; \n (aj) use in a combinatorial regime as an agent inducing macrophage activation with taxane; and \n (ak) use in a combinatorial regime as an agent inducing macrophage activation with taxol.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907728', '14907729', '13817096', '14753911', '14245738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7897774011253355
- 35 USC 102 Novelty (BERT): 0.5356024001306882
- Combined Prediction Score: 0.7643599010258707
- Mean Citation Score: 267.787678
- Max Citation Score: 348.62634
- Similarity Product: 214.4532867643046

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test